Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study

被引：59

作者：

Gomez, Virginia Esamilla ^{[1
]}

Garcia-Gutierrez, Valentin ^{[2
]}

Corral, Lucia Lopez ^{[3
]}

Cadenas, Irene Garcia ^{[4
]}

Martinez, Ariadna Perez ^{[5
]}

Malaver, Francisco J. Marquez ^{[1
]}

Caballero-Velazquez, Teresa ^{[1
]}

Sierra, Pedro A. Gonzalez ^{[6
]}

Alegria, Maria C. Viguria ^{[7
]}

Salinas, Ingrid M. Parra ^{[8
]}

Cabrera, Cristina Calderon ^{[1
]}

Vicent, Marta Gonzalez ^{[9
]}

Torres, Nancy Rodriguez ^{[1
]}

Porras, Rocio Parody ^{[10
]}

Coll, Christelle Ferra ^{[11
]}

Orti, Guillermo ^{[12
]}

Ferreiras, David Valcarcel ^{[12
]}

Llanza, Rafael De la Camara ^{[13
]}

Moles, Paula ^{[14
]}

Velazquez-Kennedy, Kyra ^{[2
]}

Mende, Maria Joao ^{[3
]}

Barrigon, Dolores Caballero ^{[3
]}

Perez, Estefania ^{[3
]}

Bofarull, Rodrigo Martino ^{[4
]}

Gerosa, Silvanna Saavedra ^{[4
]}

Sierra, Jorge ^{[4
]}

Poch, Marc ^{[5
]}

Ripa, Maria T. Zudaire ^{[7
]}

Perez, Miguel A. Diaz ^{[9
]}

Angulo, Blanca Molina ^{[9
]}

Ortega, Isabel Sanchez ^{[10
]}

Caballer, Jaime Sanz ^{[14
]}

Gomez, Juan Montoro ^{[14
]}

Tocino, Ildefonso Espigado ^{[1
]}

Perez-Simon, Jose A. ^{[1
]}

机构：

[1] Univ Seville, Univ Hosp Virgen Rocio, Inst Biomed IBIS CSIC CIBERONC, Dept Hematol,CB16 12 00480, Seville, Spain

[2] Univ Hosp Ramon y Cajal, IRYCIS, Dept Hematol, Madrid, Spain

[3] Complejo Asistencial Univ Salamanca IBSAL, Ctr Invest Canc IBMCC, Salamanca, Spain

[4] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[5] Clin Univ Hosp Valencia, Valencia, Spain

[6] Univ Hosp, Granada, Spain

[7] Hosp Navarra, Navarra, Spain

[8] Univ Hosp Miguel Servet, Zaragoza, Spain

[9] Hosp Nino Jesus, Madrid, Spain

[10] Inst Catala Oncol Hospitalet, Barcelona, Spain

[11] Inst Catala Oncol Germans Trias, Badalona, Spain

[12] Univ Hosp Vall dHebron, Barcelona, Spain

[13] Hosp La Princesa, Madrid, Spain

[14] Hosp La Fe, Valencia, Spain

来源：

BONE MARROW TRANSPLANTATION | 2020年 / 55卷 / 03期

关键词：

CONSENSUS DEVELOPMENT PROJECT; AVAILABLE THERAPY; CLINICAL-TRIALS; RAPAMYCIN; IBRUTINIB; RESISTANT; CRITERIA;

D O I：

10.1038/s41409-019-0731-x

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

Graft-versus-host disease is the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. First-line treatment is based on the use of high doses of corticosteroids. Unfortunately, second-line treatment for both acute and chronic graft-versus-host disease, remains a challenge. Ruxolitinib has been shown as an effective and safe treatment option for these patients. Seventy-nine patients received ruxolitinib and were evaluated in this retrospective and multicenter study. Twenty-three patients received ruxolitinib for refractory acute graft-versus-host disease after a median of 3 (range 1-5) previous lines of therapy. Overall response rate was 69.5% (16/23) which was obtained after a median of 2 weeks of treatment, and 21.7% (5/23) reached complete remission. Fifty-six patients were evaluated for refractory chronic graft-versus-host disease. The median number of previous lines of therapy was 3 (range 1-10). Overall response rate was 57.1% (32/56) with 3.5% (2/56) obtaining complete remission after a median of 4 weeks. Tapering of corticosteroids was possible in both acute (17/23, 73%) and chronic graft-versus-host disease (32/56, 57.1%) groups. Overall survival was 47% (CI: 23-67%) at 6 months for patients with aGVHD (62 vs 28% in responders vs non-responders) and 81% (CI: 63-89%) at 1 year for patients with cGVHD (83 vs 76% in responders vs non-responders). Ruxolitinib in the real life setting is an effective and safe treatment option for GVHD, with an ORR of 69.5% and 57.1% for refractory acute and chronic graft-versus-host disease, respectively, in heavily pretreated patients.

引用

页码：641 / 648

页数：8

共 50 条

[41] Biomarker Panel for Chronic Graft-Versus-Host Disease
Yu, Jeffrey
Storer, Barry E.
Kushekhar, Kushi
Abu Zaid, Mohammad
Zhang, Qing
Gafken, Philip R.
Ogata, Yuko
Martin, Paul J.
Flowers, Mary E.
Hansen, John A.
Arora, Mukta
Cutler, Corey
Jagasia, Madan
Pidala, Joseph
Hamilton, Betty K.
Chen, George L.
Pusic, Iskra
Lee, Stephanie J.
Paczesny, Sophie
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (22) : 2583 - U57
[42] Tocilizumab for steroid refractory acute graft-versus-host disease
Roddy, Julianna V. F.
Haverkos, Bradley M.
McBride, Ali
Leininger, Kathryn M.
Jaglowski, Samantha
Penza, Sam
Klisovic, Rebecca
Blum, William
Vasu, Sumithira
Hofmeister, Craig C.
Benson, Don M.
Andritsos, Leslie A.
Devine, Steven M.
Efebera, Yvonne A.
LEUKEMIA & LYMPHOMA, 2016, 57 (01) : 81 - 85
[43] Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre
Leung, Garret M. K.
Sim, Joycelyn P. Y.
Hwang, Yu-Yan
Chan, Thomas S. Y.
Lie, Albert K. W.
Tse, Eric
Kwong, Yok-Lam
ANNALS OF HEMATOLOGY, 2022, 101 (01) : 155 - 163
[44] Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults
Moiseev, I. S.
Morozova, E., V
Bykova, T. A.
Paina, O., V
Smirnova, A. G.
Dotsenko, A. A.
Borzenkova, E. S.
Galimov, A. N.
Gudognikova, Ya, V
Ekushov, K. A.
Kozhokar, P., V
Osipova, A. A.
Pirogova, O., V
Rudakova, T. A.
Klimova, O. U.
Tcvetkov, N. Yu
Kulagin, E. A.
Surkova, E. A.
Lapin, S., V
Rodionov, G. G.
Moiseev, S., I
Serov, Yu A.
Zubarovskaya, L. S.
Afanasyev, B., V
BONE MARROW TRANSPLANTATION, 2020, 55 (07) : 1379 - 1387
[45] Disability Related to Chronic Graft-versus-Host Disease
Hamilton, Betty K.
Storer, Barry E.
Wood, William A.
Pidala, Joseph A.
Cutler, Corey S.
Martin, Paul J.
Chen, George
Flowers, Mary E.
Lee, Stephanie J.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (04) : 772 - 777
[46] Ruxolitinib: a game changer in paediatric chronic graft-versus-host disease management?
Sisinni, Luisa
LANCET HAEMATOLOGY, 2024, 11 (08): : e553 - e555
[47] Graft-versus-host disease
Moreno, David F.
Cid, Joan
MEDICINA CLINICA, 2019, 152 (01): : 22 - 28
[48] Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease
Teshima, Takanori
Nagafuji, Koji
Henzan, Hideho
Miyamura, Koichi
Takase, Ken
Hidaka, Michihiro
Miyamoto, Toshihiro
Takenaka, Katsuto
Akashi, Koichi
Harada, Mine
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 90 (02) : 253 - 260
[49] Rituximab as salvage therapy for refractory sclerodermatous chronic graft-versus-host disease
Namdaroglu, S.
Iskender, D.
Dal, M. S.
Cakar, M. K.
Tekgunduz, E.
Altuntas, F.
HONG KONG JOURNAL OF DERMATOLOGY & VENEREOLOGY, 2019, 27 (01): : 12 - 18
[50] Ruxolitinib Treatment in an Adolescent With Chronic Graft-Versus-Host Disease Mimicking Eosinophilic Gastrointestinal Disorders: A Case Report
Getsuwan, Songpon
Tanpowpong, Pornthep
Hongeng, Suradej
Anurathapan, Usanarat
Pakakasama, Samart
Treepongkaruna, Suporn
TRANSPLANTATION PROCEEDINGS, 2022, 54 (06) : 1675 - 1678

← 1 2 3 4 5 →